Antiviral effects of hepatitis B virus S gene-specific anti-gene locked nucleic acid in transgenic mice

Table 2 Effects of anti-gene-locked nucleic acid on hepatitis B virus deoxyribonucleic acid replication and expression in transgenic mice (n = 7, mean ± SD; × 10³ IU/mL)

Groups	Before treatment	After treatment
		Day 1	Day 3	Day 5	Day 7
Blank	10.81 ± 1.15	10.80 ± 0.78	10.86 ± 1.85	10.80 ± 1.19	10.77 ± 1.25
USQ	11.12 ± 0.87	11.25 ± 0.94	11.16 ± 0.96	11.06 ± 0.85	11.08 ± 0.89
LAM	10.96 ± 1.08	10.93 ± 1.12	10.62 ± 0.89	10.07 ± 1.37	9.73 ± 1.17
Anti-S-LNA	10.92 ± 1.09	8.94 ± 0.89	6.91 ± 1.26	5.48 ± 0.97	5.79 ± 0.92
Anti-G-LNA	11.05 ± 1.25	9.12 ± 0.96	6.79 ± 1.16ab	5.42 ± 1.12ab	4.17 ± 1.29abc

^aIndicates significant differences between pre-treatment vs Anti-G-LNA (P < 0.05);

^bIndicates significant differences between Blank, USQ, LAM group vs Anti-G-LNA (P < 0.05);

^cIndicates significant differences between Anti-S-LNA vs Anti-G-LNA (P < 0.05). Values are mean ± SD. Blank: Blank control group, 5% glucose-liposome administered by tail vein injection; USQ: Unrelated sequence; LAM: Lamivudine; Anti-S-LNA: Anti-sense-LNA; Anti-G-LNA: Anti-gene-LNA; LNA: Locked nucleic acid.